While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinical trial populations.
In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center discusses how these new findings can impact the clinical use of these new agents.
Assistant Professor of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center
Associate Professor of Pediatrics and Adult Infectious Diseases
Johns Hopkins University School of Medicine
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: March 28, 2019
Expiration date: March 27, 2021